• 45th Annual Raymond James Institutional Investors Conference

    03/04/2024 | 4:35pm EST

    Watch the webcast

  • TD Cowen 44th Annual Health Care Conference

    03/05/2024 | 12:50pm EST

    Watch the webcast

Events & Presentations

  • TD Cowen 44th Annual Health Care Conference

    03/05/2024 | 9:50am PST / 12:50pm EST

    Watch the webcast

  • 45th Annual Raymond James Institutional Investors Conference

    03/04/2024 | 1:35pm PST / 4:35pm EST

    Watch the webcast

  • Myriad Genetics Fourth Quarter 2023 Financial Earnings

    02/27/2024 | 1:30pm PST / 4:30pm EST

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
04/15/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/15/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
04/10/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
04/08/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/28/2024 4/A Amendment to a previously filed 4 RTF XLS PDF HTML XBRL
03/27/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/25/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen Thumbnail

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Apr 16, 2024 | Products

Read more
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing Thumbnail

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Apr 09, 2024 | Products

Read more
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Thumbnail

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Mar 21, 2024 | Products

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics